- Home
- GNRC vs QGEN Comparison
GNRC vs QGEN Comparison
Compare GNRC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | QGEN |
|---|---|---|
| Founded | 1959 | 1986 |
| Country | United States | Netherlands |
| Employees | 9400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.2B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | GNRC | QGEN |
|---|---|---|
| Price | $266.60 | $33.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $211.75 | $45.76 |
| AVG Volume (30 Days) | 756.4K | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.36 | $8.18 |
| Revenue Next Year | $12.51 | $5.71 |
| P/E Ratio | $84.89 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $118.09 | $33.17 |
| 52 Week High | $269.58 | $57.82 |
Technical Indicators
Market Signals| Indicator | GNRC | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 76.87 | 24.85 |
| Support Level | $198.21 | N/A |
| Resistance Level | N/A | $49.16 |
| Average True Range (ATR) | 8.44 | 0.92 |
| MACD | 4.04 | -0.28 |
| Stochastic Oscillator | 90.66 | 1.56 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).